nodes	percent_of_prediction	percent_of_DWPC	metapath
Gatifloxacin—ALB—Scavenging of heme from plasma—AMBP—nephrolithiasis	0.048	0.435	CbGpPWpGaD
Gatifloxacin—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.0244	0.0274	CcSEcCtD
Gatifloxacin—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.0211	0.0237	CcSEcCtD
Gatifloxacin—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.0195	0.0219	CcSEcCtD
Gatifloxacin—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.0193	0.0217	CcSEcCtD
Gatifloxacin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—AMBP—nephrolithiasis	0.0191	0.173	CbGpPWpGaD
Gatifloxacin—Thirst—Hydrochlorothiazide—nephrolithiasis	0.0178	0.02	CcSEcCtD
Gatifloxacin—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.0178	0.02	CcSEcCtD
Gatifloxacin—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.0174	0.0196	CcSEcCtD
Gatifloxacin—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.0169	0.019	CcSEcCtD
Gatifloxacin—Migraine—Hydrochlorothiazide—nephrolithiasis	0.0167	0.0187	CcSEcCtD
Gatifloxacin—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.0164	0.0184	CcSEcCtD
Gatifloxacin—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.0159	0.0179	CcSEcCtD
Gatifloxacin—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.0155	0.0175	CcSEcCtD
Gatifloxacin—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.015	0.0169	CcSEcCtD
Gatifloxacin—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0149	0.0168	CcSEcCtD
Gatifloxacin—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.0149	0.0168	CcSEcCtD
Gatifloxacin—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0165	CcSEcCtD
Gatifloxacin—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.0144	0.0161	CcSEcCtD
Gatifloxacin—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.0137	0.0154	CcSEcCtD
Gatifloxacin—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0137	0.0154	CcSEcCtD
Gatifloxacin—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.0134	0.015	CcSEcCtD
Gatifloxacin—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.0132	0.0149	CcSEcCtD
Gatifloxacin—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.0129	0.0146	CcSEcCtD
Gatifloxacin—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.0127	0.0143	CcSEcCtD
Gatifloxacin—Sweating—Hydrochlorothiazide—nephrolithiasis	0.0125	0.0141	CcSEcCtD
Gatifloxacin—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.0125	0.014	CcSEcCtD
Gatifloxacin—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0138	CcSEcCtD
Gatifloxacin—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.0119	0.0134	CcSEcCtD
Gatifloxacin—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.0117	0.0132	CcSEcCtD
Gatifloxacin—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.0116	0.0131	CcSEcCtD
Gatifloxacin—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.0115	0.013	CcSEcCtD
Gatifloxacin—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0127	CcSEcCtD
Gatifloxacin—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0125	CcSEcCtD
Gatifloxacin—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0123	CcSEcCtD
Gatifloxacin—Erythema—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0115	CcSEcCtD
Gatifloxacin—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0113	CcSEcCtD
Gatifloxacin—Tension—Hydrochlorothiazide—nephrolithiasis	0.01	0.0113	CcSEcCtD
Gatifloxacin—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00999	0.0112	CcSEcCtD
Gatifloxacin—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00991	0.0111	CcSEcCtD
Gatifloxacin—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00987	0.0111	CcSEcCtD
Gatifloxacin—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00981	0.011	CcSEcCtD
Gatifloxacin—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00962	0.0108	CcSEcCtD
Gatifloxacin—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00956	0.0107	CcSEcCtD
Gatifloxacin—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00938	0.0105	CcSEcCtD
Gatifloxacin—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00933	0.0105	CcSEcCtD
Gatifloxacin—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00917	0.0103	CcSEcCtD
Gatifloxacin—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00915	0.0103	CcSEcCtD
Gatifloxacin—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00902	0.0101	CcSEcCtD
Gatifloxacin—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00897	0.0101	CcSEcCtD
Gatifloxacin—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00869	0.00977	CcSEcCtD
Gatifloxacin—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00869	0.00977	CcSEcCtD
Gatifloxacin—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00869	0.00977	CcSEcCtD
Gatifloxacin—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00866	0.00973	CcSEcCtD
Gatifloxacin—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.0084	0.00944	CcSEcCtD
Gatifloxacin—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00833	0.00936	CcSEcCtD
Gatifloxacin—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00833	0.00936	CcSEcCtD
Gatifloxacin—Shock—Hydrochlorothiazide—nephrolithiasis	0.00819	0.00921	CcSEcCtD
Gatifloxacin—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00816	0.00917	CcSEcCtD
Gatifloxacin—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00813	0.00914	CcSEcCtD
Gatifloxacin—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00805	0.00905	CcSEcCtD
Gatifloxacin—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00794	0.00892	CcSEcCtD
Gatifloxacin—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00778	0.00875	CcSEcCtD
Gatifloxacin—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00759	0.00853	CcSEcCtD
Gatifloxacin—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00753	0.00847	CcSEcCtD
Gatifloxacin—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00748	0.00841	CcSEcCtD
Gatifloxacin—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00743	0.00835	CcSEcCtD
Gatifloxacin—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.0074	0.00832	CcSEcCtD
Gatifloxacin—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00733	0.00824	CcSEcCtD
Gatifloxacin—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00724	0.00814	CcSEcCtD
Gatifloxacin—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00712	0.00801	CcSEcCtD
Gatifloxacin—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00686	0.00772	CcSEcCtD
Gatifloxacin—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00681	0.00766	CcSEcCtD
Gatifloxacin—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00662	0.00744	CcSEcCtD
Gatifloxacin—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00658	0.0074	CcSEcCtD
Gatifloxacin—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00658	0.0074	CcSEcCtD
Gatifloxacin—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00614	0.0069	CcSEcCtD
Gatifloxacin—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00598	0.00672	CcSEcCtD
Gatifloxacin—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00589	0.00662	CcSEcCtD
Gatifloxacin—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.0057	0.00641	CcSEcCtD
Gatifloxacin—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00551	0.00619	CcSEcCtD
Gatifloxacin—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.0053	0.00595	CcSEcCtD
Gatifloxacin—Rash—Hydrochlorothiazide—nephrolithiasis	0.00525	0.0059	CcSEcCtD
Gatifloxacin—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00525	0.0059	CcSEcCtD
Gatifloxacin—Headache—Hydrochlorothiazide—nephrolithiasis	0.00522	0.00587	CcSEcCtD
Gatifloxacin—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00495	0.00556	CcSEcCtD
Gatifloxacin—ALB—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00331	0.03	CbGpPWpGaD
Gatifloxacin—ALB—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00303	0.0274	CbGpPWpGaD
Gatifloxacin—ALB—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00303	0.0274	CbGpPWpGaD
Gatifloxacin—ALB—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00229	0.0208	CbGpPWpGaD
Gatifloxacin—ALB—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00229	0.0208	CbGpPWpGaD
Gatifloxacin—ALB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00217	0.0196	CbGpPWpGaD
Gatifloxacin—ALB—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00213	0.0193	CbGpPWpGaD
Gatifloxacin—ALB—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00213	0.0193	CbGpPWpGaD
Gatifloxacin—ALB—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.0019	0.0172	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00189	0.0171	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00189	0.0171	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00168	0.0152	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00154	0.0139	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00154	0.0139	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00117	0.0106	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00117	0.0106	CbGpPWpGaD
Gatifloxacin—ALB—Hemostasis—SLC7A9—nephrolithiasis	0.00112	0.0101	CbGpPWpGaD
Gatifloxacin—ALB—Hemostasis—DGKH—nephrolithiasis	0.00112	0.0101	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00108	0.00982	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00108	0.00982	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000966	0.00876	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000966	0.00876	CbGpPWpGaD
Gatifloxacin—ALB—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000772	0.007	CbGpPWpGaD
Gatifloxacin—ALB—Metabolism—GRHPR—nephrolithiasis	0.00067	0.00607	CbGpPWpGaD
Gatifloxacin—ALB—Metabolism—AGXT—nephrolithiasis	0.000597	0.00541	CbGpPWpGaD
Gatifloxacin—ALB—Metabolism—APRT—nephrolithiasis	0.000508	0.0046	CbGpPWpGaD
Gatifloxacin—ALB—Metabolism—SLC26A1—nephrolithiasis	0.000508	0.0046	CbGpPWpGaD
Gatifloxacin—ALB—Metabolism—AQP1—nephrolithiasis	0.000362	0.00328	CbGpPWpGaD
Gatifloxacin—ALB—Metabolism—CHRM3—nephrolithiasis	0.000327	0.00296	CbGpPWpGaD
